



**DUPIXENT<sup>®</sup>**  
(dupilumab) Injection

Now indicated  
in patients  
6+ months old in  
moderate-to-severe  
atopic dermatitis

## ADMINISTERED BY SUBCUTANEOUS INJECTION\*

### DOSING IN ADULTS (18+ YEARS) WITH ATOPIC DERMATITIS


Adults<sup>†</sup>



18+ years

#### INITIAL DOSE


TWO subcutaneous injections



Every other week  
moving forward

#### SUBSEQUENT DOSES

ONE subcutaneous injection



 DUPIXENT<sup>®</sup> pre-filled pen

 DUPIXENT<sup>®</sup> pre-filled syringe

Image adapted from DUPIXENT<sup>®</sup> Product Monograph. Please see the Product Monograph for complete dosing and administration instructions.

\* DUPIXENT<sup>®</sup> is intended for use under the guidance of a healthcare professional. A patient may self-inject DUPIXENT<sup>®</sup>, or the patient's caregiver may administer DUPIXENT<sup>®</sup>. In adolescents 12 years of age and older, it is recommended that DUPIXENT<sup>®</sup> be given by or under the supervision of an adult. The DUPIXENT<sup>®</sup> pre-filled pen is only for use in adults and adolescents aged 12 years and older. The DUPIXENT<sup>®</sup> pre-filled syringe should be given by a caregiver in pediatric patients 6 months to 11 years of age.

† No dose adjustment for body weight is recommended in adults with atopic dermatitis.

See reverse side for dosing in pediatric patients  
(6 months to 17 years) 

DUPIXENT<sup>®</sup> (dupilumab injection) is indicated for the treatment of patients aged 6 months and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT<sup>®</sup> can be used with or without topical corticosteroids.

Please consult the Product Monograph at <http://products.sanofi.ca/en/dupixent-en.pdf> for contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use. The Product Monograph is also available by calling 1-800-589-6215.





































### FREEDOM SUPPORT PROGRAM

Here to answer any questions you might have about treatment with DUPIXENT<sup>®</sup> and the support services we provide.

# ADMINISTERED BY SUBCUTANEOUS INJECTION\*

DUPIXENT® pre-filled pens are only for use in adults and adolescents aged 12 years and older.

Pediatrics (6-17 years)	Body weight	INITIAL DOSE TWO subcutaneous injections		SUBSEQUENT DOSES ONE subcutaneous injection
 12-17 years	≥60 kg	 or  300 mg +  or  300 mg	Every other week moving forward	 or  300 mg
	30 to <60 kg	 or  200 mg +  or  200 mg		 or  200 mg
	15 to <30 kg	 or  300 mg +  or  300 mg	Every 4 weeks moving forward	 or  300 mg
 6-11 years	≥60 kg	 300 mg +  300 mg	Every other week moving forward	 300 mg
	30 to <60 kg	 200 mg +  200 mg		 200 mg
	15 to <30 kg	 300 mg +  300 mg	Every 4 weeks moving forward	 300 mg
Pediatrics (6 month-5 years)	Body weight	INITIAL AND SUBSEQUENT DOSES* ONE subcutaneous injection		
 6 months - 5 years	15 to <30 kg	 300 mg	Every 4 weeks moving forward	 300 mg
	5 to <15 kg	 200 mg		 200 mg

\* No loading dose is required

 DUPIXENT® pre-filled pen

 DUPIXENT® pre-filled syringe

Image adapted from DUPIXENT® Product Monograph. Please see the Product Monograph for complete dosing and administration instructions.

[Learn more at Dupixent.ca](https://www.dupixent.ca)

\* DUPIXENT® is intended for use under the guidance of a healthcare professional. A patient may self-inject DUPIXENT®, or the patient's caregiver may administer DUPIXENT.

In adolescents 12 years of age and older, it is recommended that DUPIXENT® be given by or under the supervision of an adult. The DUPIXENT® pre-filled pen is only for use in adults and adolescents aged 12 years and older. The DUPIXENT® pre-filled syringe should be given by a caregiver in pediatric patients 6 months to 11 years of age.

Reference: DUPIXENT® Product Monograph, sanofi-aventis Canada Inc., April 14, 2023.

DUPIXENT®, Sanofi and Freedom logos are trademarks of Sanofi, used under license by sanofi-aventis Canada Inc.

REGENERON® is a trademark of Regeneron Pharmaceuticals, Inc. All rights reserved.

© 2023 sanofi-aventis Canada Inc. All rights reserved.

MAT-CA-2300551E 05/2023

sanofi | REGENERON®



**DUPIXENT®**  
(dupilumab) Injection